The Health Agency also recalls that dronedarone is contraindicated in patients with bradycardia, as well as in individuals with symptoms of heart failure at rest or during light efforts.
A clinical study in patients at high cardiovascular risk was terminated prematurely due to a significant increase in the frequency of the occurrence of major cardiovascular events, such as cardiovascular death, stroke or hospitalizations. .
While the High Authority for Health (HAS) issued an unfavorable opinion for the maintenance of the reimbursement of Multaq, the Minister of Health Xavier Bertrand announced, on July 18, that he would not oppose this delisting. . He also recalled that the question of keeping Multaq on the market would arise again at the start of the school year when the conclusions of the reassessment of the benefit / risk ratio of the drug would be published.
